ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 1,903 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $30.00, for a total value of $57,090.00. Following the completion of the sale, the executive vice president now directly owns 83,059 shares of the company’s stock, valued at approximately $2,491,770. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) traded down 0.79% on Monday, reaching $29.01. The company had a trading volume of 1,045,436 shares. The firm’s market capitalization is $3.54 billion. ACADIA Pharmaceuticals Inc. has a 52-week low of $20.68 and a 52-week high of $40.83. The stock’s 50-day moving average price is $28.10 and its 200 day moving average price is $32.03.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.01. ACADIA Pharmaceuticals had a negative net margin of 948.93% and a negative return on equity of 63.07%. The firm had revenue of $15.30 million during the quarter, compared to analysts’ expectations of $15.17 million. During the same period in the prior year, the company earned ($0.45) EPS. On average, equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post ($2.83) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/06/26/acadia-pharmaceuticals-inc-acad-evp-glenn-baity-sells-1903-shares.html.

Several equities research analysts recently commented on the company. Zacks Investment Research raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $49.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, April 5th. Rodman & Renshaw reaffirmed a “buy” rating and issued a $60.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, May 22nd. BidaskClub upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 21st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $47.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, April 12th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the company’s stock. ACADIA Pharmaceuticals has an average rating of “Hold” and an average target price of $42.88.

A number of hedge funds have recently made changes to their positions in ACAD. Russell Investments Group Ltd. acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth $145,000. State Board of Administration of Florida Retirement System boosted its position in ACADIA Pharmaceuticals by 8.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 111,511 shares of the biopharmaceutical company’s stock worth $3,216,000 after buying an additional 9,134 shares during the last quarter. State Street Corp boosted its position in ACADIA Pharmaceuticals by 7.9% in the fourth quarter. State Street Corp now owns 3,354,026 shares of the biopharmaceutical company’s stock worth $96,728,000 after buying an additional 246,198 shares during the last quarter. A.R.T. Advisors LLC purchased a new position in ACADIA Pharmaceuticals during the fourth quarter worth $348,000. Finally, Seven Eight Capital LP purchased a new position in ACADIA Pharmaceuticals during the fourth quarter worth $320,000. 97.19% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Stock Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.